Amgen (NASDAQ:AMGN) is in a bit of a conundrum.

The big biotech's talimogene laherparepvec -- T-VEC for short -- passed its primary endpoint, lowering the durable response rate in melanoma patients. But a secondary endpoint of overall survival just missed being statistically significant, with a p-value of 0.051. The Food and Drug Administration typically likes to see a p-value of less than 0.05, which equates to less than a 5% chance that the observed difference was due to chance alone.

In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss Amgen's chances for success, whether it will be able to compete with Bristol-Myers Squibb's (NYSE:BMY) Yervoy, and its potential to be used in combination with Yervoy and Merck's (NYSE:MRK) anti-PD-1 antibody MK-3475.

Brian OrelliMax Macaluso, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.